|Videos|December 22, 2017
Platinum Sensitivity and PARP Inhibition in Ovarian Cancer
Advertisement
Episodes in this series
Advertisement
Related to this article
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
Advertisement
Advertisement
Trending on OncLive
1
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
2
Five Under 5: Top Oncology Videos for the Week of 10/5/2026
3
Armenia Grants First Marketing Authorizations to Botensilimab Plus Balstilimab in Previously Treated MSS mCRC
4
RYZ101 Meets Primary PFS End Point in Phase 3 ACTION-1 Trial for Post–Lutetium-177 GEP-NETs
5